血清GGT、AFU、ALP及AFP检测对肝癌的临床价值

The clinical value of determining serum GGT,AFU,ALP and AFP in the diagnosis of hepatic carcinoma

目的:探讨谷氨酰氨基转移酶(GGT)、α-L-岩藻糖苷酶(AFU)、碱性磷酸酶(ALP)以及甲胎蛋白(AFP)对肝癌的诊断价值。方法:GGT采用速率法,AFU、ALP采用酶法,AFP用酶联免疫法,分别测定原发性肝癌组56例、转移性肝癌组64例、其他肝病组50例与正常对照组77例血清标本中GGT、AFU、ALP及AFP含量,结果均采用统计学方法分析。结果:原发性肝癌组、转移性肝癌组中GGT、AFU、ALP、AFP含量显著高于其他肝病组和正常对照组(P<0.01);其诊断肝癌(包括原发与转移)的阳性率分别为87.7%、78.9%、85.6%、65.3%和70.3%、45.4%、80.3%、57.3%,与其他肝病组和正常对照组阳性率比较,差异有高度统计学意义(P<0.01)。四个指标联合应用对原发性肝癌和转移性肝癌的阳性率分别为97.2%和82.6%,与其他肝病组和正常对照组阳性率比较,差异有高度统计学意义(P<0.01)。结论:GGT、AFU、ALP及AFP联合检测可以明显提高肝癌诊断的准确性。

Objective： To study the clinical value of γ-glutamyhransferase （GGT）, α-L-fucosidase （AFU） and alkali phosphatase （ALP）, alpha fetoprotein （AFP） in the diagnosis of hepatic carcinoma. Methods： Velocity method was adopted to measure GGT, enzymic method was used in AFU and ALP measurement, and ELISA assay was used in AFP measurement. The activities of serum GGT, AFU, ALP and AFP were detected in 56 patients with primary hepatic carcinoma, 64 patients with secondary liver cancer, 50 patients with other kinds of hepatic diseases and 77 normal people. All results were statistically analyzed. Results： The activities of serum GGT, AFU, ALP and AFP in patients with primary or secondary liver cancer were significantly higher than those of other kinds of hepatic diseases and normal people （P〈0.01）. The positive rates of GGT, AFU, ALP and AFP were 87.7%, 78.9%, 85.6%, 65.3% and 70.3%, 45.4%, 80.3%, 57.3% respectively, they were higher than those of other kinds of hepatic diseases and normal people （P〈0.01）. At the same time, with the four index together, the positive rates were 97.2% and 82.6%, they were higher than that of other kinds of hepatic disease and normal people （P〈0.01）. Conclusion： Simultaneously detecting the serum enzymatic activities of GGT, AFU, ALP and AFP can help the early diagnosis of hepatic carcinoma.